Marker Therapeutics, Inc.

Monthly Archives: December 2018

Marker Therapeutics Exits ASH An Optimist. Should That Be Enough For You?

Marker Therapeutics has emerged out of a merger with Tapimmune to push forward new cell-based cancer vaccines.
Read More

Marker Therapeutics to Present at the Tumor Targeted Lymphocytes Summit

President and CEO, Peter L. Hoang, will be participating at the Tumor Targeted Lymphocyte Summit.
Read More